Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT00623831 | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen | completed | Phase 1 | 17 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT04509557 | [177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer. | completed | Phase 1 | 30 | FutureChemINDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
| NCT02064036 | Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate(CCRO025) | completed | Phase 1 | 17 | University of California, DavisOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT00199849 | NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine | completed | Phase 1 | 18 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT03709550 | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT01174199 | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 1 | 13 | Roswell Park Cancer InstituteOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT01197625 | Vaccine Therapy in Curative Resected Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 30 | Oslo University HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04470843 | Impact of Acetazolamide in Reducing Referred Postoperative Pain | completed | Phase 1 | 33 | Medical College of WisconsinOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT04685811 | Evaluation of PSMA Antagonist Produced by Two Different Methods | completed | Phase 1 / Phase 2 | 16 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT04279561 | Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer | terminated | Phase 1 | 9 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT03262103 | Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer | completed | Phase 1 | 13 | Ashutosh Kumar TewariOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02494921 | LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC | completed | Phase 1 / Phase 2 | 43 | Rahul AggarwalOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT03934827 | MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour(MICROBIOME) | unknown | Phase 1 | 120 | Imperial College LondonOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05191017 | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | withdrawn | Phase 1 / Phase 2 | 0 | Nuvation Bio Inc.INDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT01310192 | Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography | completed | Phase 1 | 20 | Queen's Medical CenterOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT02012296 | Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 88 | University of ChicagoOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT04634344 | Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC | terminated | Phase 1 | 16 | Dizal PharmaceuticalsINDUSTRY | 2 | Jul 11, 2022 | clinicaltrials |
| NCT03367819 | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 44 | SanofiINDUSTRY | 5 | May 16, 2022 | clinicaltrials |
| NCT03780075 | Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT02121639 | Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy(ProCAID) | completed | Phase 1 / Phase 2 | 160 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT03444844 | Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 60 | Five Eleven Pharma, Inc.INDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT04300673 | Radio Guided Lymph Node Dissection in Oligometastatic Prostate Cancer Patients(DETECT) | unknown | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT02913131 | Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies | terminated | Phase 1 / Phase 2 | 23 | Rahul AggarwalOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT00779168 | White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05286840 | 64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer | unknown | Phase 1 / Phase 2 | 150 | Luke Nordquist, MDOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT03441464 | Feasibility of the LUM Imaging System for Detection of Prostate Cancer | terminated | Phase 1 / Phase 2 | 9 | Lumicell, Inc.INDUSTRY | 1 | Feb 25, 2022 | clinicaltrials |
| NCT01826838 | Study of Dasatinib, Androgen Deprivation Therapy and Radiation(BrUOGPR255) | withdrawn | Phase 1 | 0 | Brown UniversityOTHER | 0 | Feb 24, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT02250014 | The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer | completed | Phase 1 | 19 | University of Colorado, DenverOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT02653248 | SBRT for Organ Confined Prostate Cancer | completed | Phase 1 | 36 | Northwell HealthOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | completed | Phase 1 | 179 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT03412786 | Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases | completed | Phase 1 | 20 | Herlev HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT02207504 | Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT03793543 | Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer | completed | Phase 1 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT05156424 | A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer | unknown | Phase 1 / Phase 2 | 24 | Kira MurphyOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT02711956 | A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 75 | Zenith EpigeneticsINDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
| NCT02767921 | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer | terminated | Phase 1 | 2 | University of Southern CaliforniaOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT03120832 | Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients | completed | Phase 1 | 12 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Nov 12, 2021 | clinicaltrials |
| NCT02280317 | Dose Finding Safety Study of VAL201 in Cancer Patients(VAL201-001) | completed | Phase 1 / Phase 2 | 12 | ValiRx PlcINDUSTRY | 0 | Nov 8, 2021 | clinicaltrials |
| NCT04555343 | Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention | completed | Phase 1 / Phase 2 | 14 | Fraser HealthOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT04374240 | A Clinical Trial of AdNRGM Plus CB1954 in Prostate Cancer(AdUP) | completed | Phase 1 | 18 | University of BirminghamOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT04574401 | A Phase 1 Study of IS-002 Injection in Patients Undergoing Robotic Prostatectomy | completed | Phase 1 | 24 | Intuitive SurgicalINDUSTRY | 1 | Oct 22, 2021 | clinicaltrials |
| NCT03136640 | ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 23 | Modra PharmaceuticalsINDUSTRY | 1 | Oct 19, 2021 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Dec 2, 2022source: clinicaltrials